BioNTech is on the verge of returning to its oncology roots with potentially its first commercial cancer drug. Yet, to Chief Commercial Officer Annemarie Hanekamp, the upcoming launch is less of a standalone milestone and more of a strategic springboard for a far more critical pipeline product.
Source: FiercePharma
